Cell Culture Technology– category –
-
Chime Biologics Unveils AI-Driven Biomanufacturing Future with New Wuhan GMP-2 Facility and 100+ Bioreactor Megafactory Vision
BioPharma APAC China Overview Chime Biologics has significantly bolstered its biopharmaceutical manufacturing capabilities with the opening of its GMP-2 facility in Wuhan, China, equipped with eight Cytiva 2,000-liter single-use Xcellere... -
Pioneering Off-the-Shelf Immunotherapy: CellFiber and Tidewave Bio Partner on Scalable 3D Cell Culture Manufacturing
BioSpace Japan Overview CellFiber and Tidewave Bio have launched a collaborative research program to evaluate CellFiber's proprietary 3D cell encapsulation technology for scalable immune cell manufacturing. This proof-of-concept study, l... -
AI-Powered Biologics: AstraZeneca and CSPC Forge Strategic Manufacturing Alliance in China
Fierce Pharma China Overview AstraZeneca and CSPC Pharmaceutical have formed a joint venture to establish a new biopharmaceutical manufacturing facility in Shijiazhuang, China. CSPC will contribute AI-driven GMP systems and manufacturing... -
Gene Therapy’s Backbone: Oxford Biomedica Acquires ABL Europe, Driving Consolidation in Viral Vector Manufacturing
Industry News UK Overview The viral vector manufacturing market, crucial for gene therapy commercialization, is experiencing accelerated consolidation driven by M&A, exemplified by Oxford Biomedica's acquisition of ABL Europe. This s... -
AGC Biologics Accelerates Cell & Gene Therapy Commercialization with Expanded Viral Vector Manufacturing Platforms
Facebook (AGC Biologics page) USA Overview AGC Biologics is significantly expanding its specialized viral vector manufacturing services for the rapidly growing cell and gene therapy (CGT) sector. The company now offers comprehensive adhe... -
APAC’s Biomanufacturing Ascent: Australia Pioneers Viral Vector Production for Gene Therapies
Industry Publication Australia Overview The Asia-Pacific (APAC) region is rapidly accelerating its specialized manufacturing capabilities for high-value modalities like viral vectors and cell therapies, moving beyond traditional API prod... -
Pre-owned Miltenyi Biotec CliniMACS Instrument Hits Secondary Market, Broadening Access to Advanced Cell Separation
LabX.com USA Overview A used Miltenyi Biotec CliniMACS Instrument cell separator (Model 44085), manufactured in October 2017, has been listed on the online lab equipment marketplace LabX.com. This sophisticated device is engineered for e... -
Enzene Unveils ‘NeX’ Partnership Model to Globalize Biologics Production via Continuous Manufacturing
PharmaSource India Overview Enzene has launched 'NeX,' an end-to-end partnership model designed to establish regional biopharmaceutical manufacturing capabilities globally. Leveraging its fully connected continuous manufacturing platform... -
Cerebral Organoids Enter Industrial Era: Automation Drives Standardization and High-Throughput Scaling for Neuroscience Innovation
Newfund Capital USA Overview Cerebral organoid production is undergoing a transformative industrialization, driven by automated platforms for iPSC generation, expansion, and differentiation. This technological leap standardizes manufactu... -
Off-the-Shelf Advantage: How Scalable Manufacturing Drives Clinical Success for Combination Cell Therapies
Industry Publication USA Overview A recent industry analysis underscores the critical role of manufacturability and scalability from the earliest stages of development for the clinical success of cell therapies, particularly complex comb...
